

Ontogeny of Phase I Metabolism of Drugs

J. Steven Leeder, PharmD, PhD
Children's Mercy Hospital
Kansas City, MO

Disclosures

In the past 12 months, I have no relevant financial relationships with the manufacturer(s) of any commercial product(s) and/or providers of commercial services discussed in this presentation.

Grant Support

U54 HD090258: Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids: GOLDILOCKS (Leeder, PI)

R01 HD081299: PBPK Prediction of Ontogeny Mediated Alteration in Drug Elimination (Prasad, PI)

K23 HD091362: Mentored Patient-Oriented Research Career Development Award (Lewis, PI)

T32 HD069038: Research Fellowship Program in Pediatric Clinical and Developmental Pharmacology (Abdel-Rahman, Leeder co-Pis)

Presentation Goals


- Review the different sources of data contributing to current knowledge related to developmental trajectories of Phase 1 pathways
- Illustrate the challenges related to interpreting CYP ontogeny *in vivo* in the context of competing pathways
 - Indomethacin for treatment of PDA in the NICU (Tamorah Lewis, MD, PhD)
- Present new data regarding the ontogeny of scaling factors used to translate CYP developmental trajectories based on *in vitro* data to simulated drug disposition *in vivo*

Sources of “Ontogeny” Data: *In vitro*


- mRNA expression
 - qPCR
 - RNA-Seq (alternative splicing)
- Protein expression
 - Immunoblotting (antibody specificity; dynamic range)
 - Quantitative proteomics
- Catalytic activity (metabolite formation)
 - Specificity of probe substrates
 - Contribution of competing pathways

Ontogeny of CYP2B6


- Data analysis challenges related to tissue source and quality
- Immunoreactive protein detected in fetal liver, but no catalytic activity; no activity in 5 pediatric and 2 adult samples, and low (<LLOQ) in 21 pediatric and 2 adult
- Linear regression not appropriate
- Age-dependent break points by partitioning analysis
- No detectable genetic effect



Ontogeny of CES1 and CES2



Ontogeny of CES1 and CES2



Developmental Trajectory of CES1

- Data sparse at ages where developmental trajectory is steepest
- Linear regression not appropriate
- Microsomal and cytosolic expression for CES1 and CES2

Ontogeny equation^a

$$F = \left(\frac{Adult_{max} - F_{birth}}{Age50^n + Age^n} \right) \times Age^n + F_{birth}$$

CES1 ontogeny parameters^b

F_{birth} , $Adult_{max}$, $Age50$, and n : 0.20, 1, 1.10, and 0.56, respectively^b

^aEquation terms: $Adult_{max}$, maximum average relative protein abundance; Age, age in years of the subject at the time of sample collection; $Age50$, age in years at which half-maximum adult protein abundance is obtained; F , fractional protein abundance in adult samples; F_{birth} , fractional protein abundance (of adult) at birth; n , exponential factor.

^bSince CES1 is functionally active in both microsomal and cytosolic fractions, the ontogeny equation was derived based on the total microsomal plus cytosolic abundance of CES1 per gram of liver tissue. To do so, reported values of milligram of microsomal and cytosolic proteins per gram liver tissue (39.8 and 80.7 mg/ml, respectively) were used to first obtain microsomal and cytosolic CES1 abundance per gram of liver tissue. Then, the total microsomal plus cytosolic abundance of CES1 per gram of liver tissue was derived by adding the two values. Finally, the adult normalized fractional values were derived by considering $Adult_{max}$ to be equal to 1.




Sources of “Ontogeny” Data: *In vivo*

- Pharmacokinetic studies of model substrates:
 - Disappearance (clearance) of parent drug/probe substrate
 - Challenge: multiple metabolites, different pathways
 - e.g., atomoxetine
 - Formation of pathway-specific metabolite most relevant
 - Challenge: IV vs oral administration
 - Gut vs hepatic metabolite formation
 - Challenge: Plasma or urinary metabolite data?
 - To assess ontogeny, plasma metabolite AUC data must be formation rate-limited; urine data allow estimate of fractional contribution of pathway
 - Cross-sectional vs longitudinal data

Ontogeny of Sildenafil Disposition in Neonates: (Hepatic CYP3A)



Day 1:

Clearance = 0.84 L/h or 8.05
L/h/70 kg
(*N*-desmethyl metabolite
predicted to be 11% of parent)





Day 7:

Clearance = 2.58 L/h or 24.7
L/h/70 kg
(*N*-desmethyl metabolite
predicted to be 71% of parent)






Role for CYP2C9?







Cross-Sectional vs Longitudinal Studies: Indomethacin in Patent Ductus Arteriosus




CYP Ontogeny... Which Developmental Trajectory?




CYP Ontogeny... Which Developmental Trajectory?



Ontogeny of Scaling Factors: MPPGL




Barter *et al*, Curr Drug Metab 2007; 8:33-41




Barter *et al*, DMD 2008; 36:2405-2409


Ontogeny of Scaling Factors: MPPGL



$$\text{MPPGL} = 10^{1.434 + 0.008 \times \text{Age} - 0.00038 \times \text{Age}^2 + 0.000024 \times \text{Age}^3}$$




Ontogeny of Scaling Factors: MPPGL




Group	NICHD Age Range		
0	Fetal		n = 5
1	Infancy	(28 d-12 m)	n = 20
2	Toddler	(13 m-2 y)	n = 9
3	Early Child	(2y-5y)	n = 21
4	Middle	(6y-11y)	n = 32
5	Early Adol	(12y-18y)	n = 47
6	Adult_1	(19y-50y)	n = 16
7	Adult_2	(>50y)	n = 15

If Most CYPs Have A Similar Developmental Trajectory, What is the Ontogeny of Total CYP Content?



Group	NICHD Age Range		
0	Fetal		n = 1
1	Neonate	(Birth-27 d)	n = 4
2	Infancy	(28 d-12 m)	n = 18
3	Toddler	(13 m-2 y)	n = 9
4	Early Child	(2y-5y)	n = 21
5	Middle	(6y-11y)	n = 40
6	Early Adol	(12y-18y)	n = 47
7	Adult_1	(19y-50y)	n = 33
8	Adult_2	(>50y)	n = 19

Ontogeny of Total Hepatic CYP Content



Summary and Challenges

- For an individual drug, impact of “ontogeny” on clearance is greatest when PGx contribution $\rightarrow 0$, and fraction metabolized $\rightarrow 1$
- Quantitative proteomic data may allow refinement of equations describing developmental trajectories
- Developmental trajectories derived from *in vivo* data may more informative for predictive modeling and simulation
- Experience with one CYP substrate is not directly applicable to other substrates for same pathway (Calvier *et al* CPT-PSP 2018: 7:174-185)
 - Consider ontogeny and genetic variation for all ancillary/competing pathways

Summary and Challenges

- Cross-sectional data probably sufficient for “population” purposes
 - Data generally are sparse for periods where the velocity of change is greatest
 - Extensive inter-individual variability obscures developmental changes that may be occurring during critical periods of change, such as around puberty
- Longitudinal data more informative at the level of individual patients
 - Detecting patterns that may not be apparent from cross-sectional data
 - Potential implications for systemic exposure and clinical response
 - Data capture needs to be sufficiently long to observe developmental changes
- Challenge: Collecting the data